Emerald Mutual Fund Advisers Trust Mirati Therapeutics, Inc. Transaction History

Emerald Mutual Fund Advisers Trust

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 29, 2021	SELL	$144.0 - $179.73 $3.92 Million - $4.89 Million	-27,224 Closed	0 $0
Q1 2021 Apr 29, 2021	SELL	$158.92 - $221.61 $11.1 Million - $15.4 Million	-69,559 Reduced 71.87%	27,224 $4.66 Million
Q4 2020 Jan 29, 2021	SELL	$162.05 - $240.27 $12.3 Million - $18.2 Million	-75,594 Reduced 43.85%	96,783 $21.3 Million
Q2 2020 Jul 28, 2020	SELL	$72.01 - $120.39 $2.82 Million - $4.72 Million	-39,220 Reduced 18.54%	172,377 $19.7 Million
Q1 2020 Apr 30, 2020	BUY	$69.78 - $116.21 $1.6 Million - $2.67 Million	22,946 Added 12.16%	211,597 $16.3 Million
Q4 2019 Jan 29, 2020	BUY	$70.76 - $128.86 $4.29 Million - $7.81 Million	60,580 Added 47.3%	188,651 $24.3 Million
Q3 2019 Oct 31, 2019	BUY	$77.91 - $109.6 $9.98 Million - $14 Million	128,071 New	128,071 $9.98 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Emerald Mutual Fund Advisers Trust, based on Form 13F filings with the SEC.

Stay updated on Emerald Mutual Fund Advisers Trust with notifications on news.